Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties

Chronic lymphocytic leukemia (CLL) - the most common subtype of hemoblastoses (22-30%). It can have aggressive or indolent course, with diverse clinical symptoms. The foundation of this diversity is the molecular features of the disease. The incidence of CLL in Russia is 6.67 per 100 000 population....

Full description

Saved in:
Bibliographic Details
Published inSovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia Vol. 18; no. 5; pp. 16 - 19
Main Author Samoylova, O.S.
Format Journal Article
LanguageEnglish
Published IP Habib O.N 01.12.2016
Subjects
chronic lymphocytic leukemia
ibrutinib
obinutuzumab
Online AccessGet full text

Cover

More Information
Summary:Chronic lymphocytic leukemia (CLL) - the most common subtype of hemoblastoses (22-30%). It can have aggressive or indolent course, with diverse clinical symptoms. The foundation of this diversity is the molecular features of the disease. The incidence of CLL in Russia is 6.67 per 100 000 population. By 2016 several novel therapies for CLL have been registered in Russia, including ibrutinib and obinutuzumab, but the implementation of the novel drugs into daily practice meets certain difficulties. This article describes some of them based on the experience on the N.A.Semashko Nizhny Novgorod regional clinical hospital.
ISSN:1815-1434
1815-1442
DOI:10.26442/1815-1434_2016.5.16-19